SPHS Sophiris Bio, Inc.

0  0%
Previous Close 2.61
Open 2.61
Price To book 5.48
Market Cap 78.29M
Shares 30,111,000
Volume 172,478
Short Ratio 5.55
Av. Daily Volume 399,963

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b six-month biopsy data for all patients in late 2017 or early 2018 with final biopsy data due 3Q 2018.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio to Present at 16th Annual Needham Healthcare Conference
  2. SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway
  3. Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights
  4. Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress
  5. Sophiris Bio to Present at 29th Annual ROTH Conference
  6. Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference
  7. Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd
  8. Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  9. Three Biotech Companies With Large Upside Potential
  10. Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
  11. Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital
  12. SPHS: Initiating on Sophiris Bio, Inc.; Developing Novel Treatments for Urologic Conditions
  13. 5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside
  14. Top Analyst Upgrades and Downgrades: Apple, BHP Billiton, Broadcom, McDonald’s, Sophiris, Tech Data and More
  15. Sophiris Bio Closes Underwritten Public Offering
  16. Sophiris Bio Inc. (NASDAQ:SPHS): Sabby Capital Reports Large New Stake
  17. Look Out Below! What’s the Deal With These 5 Falling Stocks?